Mark A Hoffman1, John A Blessing, Samuel S Lentz. 1. Division of Hematology-Oncology, Long Island Jewish Medical Center, Campus of the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA. hoffman@lij.edu
Abstract
OBJECTIVE: To estimate the antitumor efficacy of dolastatin-10 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of dolastatin-10 in these patients. METHODS: Patients received dolastatin-10 400 microg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. RESULTS: Of 28 patients evaluable for response, there were no complete or partial responses. Seven patients had stable disease and 21 patients had increasing disease. CONCLUSION: Dolastatin-10 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.
OBJECTIVE: To estimate the antitumor efficacy of dolastatin-10 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of dolastatin-10 in these patients. METHODS:Patients received dolastatin-10 400 microg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. RESULTS: Of 28 patients evaluable for response, there were no complete or partial responses. Seven patients had stable disease and 21 patients had increasing disease. CONCLUSION:Dolastatin-10 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.
Authors: Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh Journal: Gynecol Oncol Date: 2011-07-12 Impact factor: 5.482
Authors: Hedy L Kindler; Peter K Tothy; Robert Wolff; Richard A McCormack; James L Abbruzzese; Sridhar Mani; Kurombi T Wade-Oliver; Everett E Vokes Journal: Invest New Drugs Date: 2005-10 Impact factor: 3.850
Authors: Lydia Usha; Michael W Sill; Kathleen M Darcy; Doris M Benbrook; Jean A Hurteau; David P Michelin; Robert S Mannel; Parviz Hanjani; Koen De Geest; Andrew K Godwin Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482